NEW

S4

Mometamax® Ultra

One Dose. Healthy Ears. Happy Dog.

Canine otitis externa

- Otitis externa may affect up to 1 in 7 dogs seen in practice.[1,2]
- Can be acute or acute exacerbation of recurrent otitis externa.
- Up to 90 % of cases involve a microbial agent.[3,4]
- Most of these infections are mixed, with commensal organisms, Malassezia and Staphylococci being the most prevalent combination.[3,4,5]
- True primary pathogens are rare.[6]
- Cytology should be performed in all cases to determine the type of infection[6]:
- Effective treatment requires that all the underlying factors leading to persistent or recurrent infections are identified and managed: [6,7]





Primary[5,6]

- Allergies
- Parasitism
- Foreign bodies
- Masses
- Endocrinopathies

Predisposing[5,6]

- Pendulous pinnae
- Hairy narrow canals
- Overcleaning
- Humidity
- Swimming

Perpetuating[5,6]

- Nodular and glandular hyperplasia (“cobblestone”)
- Epidermal and dermal thickening
- Ear canal stenosis

3 IN 1

THE UNIQUE, SINGLE DOSE OTITIS EXTERNA TREATMENT YOU CAN COUNT ON

MSD Animal Health

The Science of Healthier Animals™



Features

- Multi-use, 20 dose bottle.
- 0,8 mℓ dose per ear.
- For use in dogs from 3 months and 2,4 kg.
- Provides at least 4 weeks efficacy.
- Store below 30 °C.
- Discard 3 months after opening the bottle.
- Locally acting with little or no systemic exposure of the active ingredients.[14]
- Preservative free.

1 Gentamicin

- Broad-spectrum bactericidal antibiotic.
- Rapidly kills susceptible gram-positive and gram-negative bacteria, including *Staphylococcus pseudintermedius, Pseudomonas aeruginosa, Streptococcus* spp., *Proteus* spp., *Escherichia coli.*[8,9]

2 Posaconazole

- Highly potent against susceptible yeast, including *Malassezia pachydermatis.*
- **40-100x MORE POTENT** *in vitro* against *M. pachydermatis* than clotrimazole, miconazole, nystatin and terbinafine.[10,11]

3 Mometasone Furoate

- A corticosteroid with high topical potency and few systemic side effects.
- Has anti-inflammatory and anti-pruritic properties.[9]

How to administer

No need to insert the syringe into the ear canal. Administer at the entrance of the ear canal and allow to flow down via gravity to coat the horizontal and vertical ear canal.

1. **Clean** and **dry** the dog's ears
2. Before use **shake** the product well
3. Draw the **0,8 mℓ** dose into the syringe provided
4. Place the tip of the syringe at the entrance of the external ear and administer
5. Massage the ear gently after application.

Do not clean the ear canal for at least 28 days after administration.

Field efficacy study

In a field study 12 of 33 dogs with a mixed culture of *Staphylococcus pseudintermedius* and *Malassezia pachydermatis*, the OTIS-3 scale* was used to assess response to treatment at 2 and 4 weeks after MOMETAMAX® ULTRA was applied. Treatment was deemed successful when there was a significant reduction of Total Clinical Score (TCS) to ≤ 4 at 2 weeks and ≤ 3 at 4 weeks:

- **100 % HAD HEALTHIER EARS** by 2 weeks after treatment (TCS ≤ 4).
- **100 % HAD HEALTHY EARS** by 4 weeks after treatment (TCS ≤ 3).
- **100 % OF DOGS WERE HEALTHY** with no treatment related adverse effects seen.
- **81 % MICROBIOLOGICAL CURE** of *M. pachydermatis* by 4 weeks.

This field study also measured the improvement in key clinical signs of otitis externa (measured by percentage reduction of TCS using the OTIS-3 scale) at 1, 2, 4 and 6 weeks.



* OTIS-3 (Otitis Index Score 3) uses a 0 to 3 scale to assess four individual criteria (erythema, oedema/swelling, erosion/ulceration, and discharge) to evaluate severity and response to treatment. The scores for each criteria are combined to give a Total Clinical Score that can range from 0 (no signs) to 12 (most severe).[13] ‡ Drug concentrations measured in ear wax (µg/g) in healthy dogs.

Demonstrated safety

1 SINGLE DOSE FROM 12 WEEKS[9,12]

WELL TOLERATED[12,14]

FEW SYSTEMIC EVENTS[14]

Field Study[12]: 276 client owned dogs from 12 weeks of age and 2,4 kg had MOMETAMAX® ULTRA applied on Day 0, and efficacy assessed at 2 and 4 weeks. **No treatment-related adverse reactions** were observed when treated at the recommended dosing frequency.

Target Animal Safety Study[14]: **Dogs were administered 1x, 3x and 5x the recommended dose every 2 weeks for a total of 3 treatments.** Locally, minimal to mild atrophy of the external ear canal epidermis and the tympanic epithelial lining were observed. Systemically, minimal to mild adrenocortical atrophy was observed however ACTH stimulation at the end of the study elicited an increase in cortisol level in all treatment groups, indicating sufficient adrenal function. **All adverse effects observed were of low severity, reversible and consistent with glucocorticoid administration.**

S4 Mometamax® Ultra

THE UNIQUE, SINGLE-DOSE OTITIS EXTERNA TREATMENT YOU CAN COUNT ON

More confidence

- **Single-dose treatment.**
- **Provides at least 4 weeks efficacy.[9]**
- **Well tolerated, effective, convenient.**

Better compliance

- **For veterinary professional use only.**
- **Correct dosage ensured.**
- **No at-home administration required.**

Unique ingredients 3 IN 1

- **Gentamicin:** broad-spectrum bactericidal antibiotic with activity against gram-positive and gram-negative bacteria.
- **Posaconazole:** novel antifungal that is highly potent against susceptible yeast including *Malassezia pachydermatis*.
- **Mometasone Furoate:** corticosteroid with high topical potency.

References: 1. Perry LR, MacLennan B, Korven R, et al. Can Vet J. 2017;58:168-174. **2.** O'Neill DG, Church DB, McGreevy PD, et al. PLoS One. 2014;9:e90501. **3.** Petrov V, Zhelev G, Marutsov P, et al. Bulg J Vet Med. 2018;22:1-10. **4.** Szewczuk MA, Zych S, Sablik P. Slov Vet Res. 2020;57:33-43. **5.** Lyskova P, Vydrzalova M, Mazurova J. J Vet Med A. 2007;54:559-563. **6.** Nuttall T. In Practice 2016; 17-21. **7.** Nuttall T. JAVMA. 2023;261:10-22. **8.** Paterson S. Small Anim Pract. 2016;57:668-678. **9.** Package insert **10.** Bourdeau P, Marchand AM, Etore F. Vet Dermatol. 2004;15:46. **11.** Peano A, Johnson E, Chiavassa E, et al. J Fungi. 2020;6:93 **12.** Heuer L, Wilhelm C, Roy O, et al. Vet Record. 2024; e3955. **13.** Nuttall T. Vet Dermatol. 2014;25:530-7. **14.** Mometamax® Ultra Registration Dossier

S4 **MOMETAMAX® ULTRA** Reg. No. 23/14.3/05 (Act 101/1965) Each 0,8 mℓ contains: Gentamicin (sulfate) equivalent to 6880 IU (6,88 mg), Posaconazole 2,08 mg, and Mometasone furoate (monohydrate) equivalent to 1,68 mg.

Intervet South Africa (Pty) Ltd | Reg. No. 1991/006580/07 | 20 Spartan Road, Spartan, 1619, RSA
Private Bag X2026, Isando, 1600, RSA | Tel: +27 (0)11 923 9300 | E-mail: msdahza@msd.com | E-mail: salesordersmsd@msd.com
www.msd-animal-health.co.za | ZA-MTMU-250600002

MSD Animal Health
The Science of Healthier Animals™